AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29985719
Drug: Sham BEMER
RxNorm normalized name: Beser
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sham BEMER treatment combined with rehabilitation
Trial: 30971301
Drug: Definitive concurrent
RxNorm normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definitive concurrent chemoradiotherapy (DCRT) with intensity-modulated radiation therapy (IMRT) at 50 Gy/25 fractions and basic chemotherapy with 5-fluorouracil regimens
Trial: 26115797
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (7.5 mg/kg every 3 weeks, continued with up to 12 further cycles)
Trial: 26115797
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (in poor prognosis subgroup)
Trial: 26115797
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (in poor prognosis subgroup)
Trial: 26115797
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (in non-high-risk patients)
Trial: 26115797
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (in non-high-risk patients)
Trial: 22327088
Drug: Placebo (glucose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glucose: 30 mg·d⁻¹)
Trial: 16102683
Drug: Propofol TCI
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol TCI (Diprifusor pharmacokinetic model) starting at 4 microg/mL, adjusted by 0.4 microg/mL step size
Trial: 2860740
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg) plus placebo
Trial: 6337428
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg) plus Persantine (75 mg) four times daily
Trial: 17369904
Drug: Poetam (affinity‐purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poetam (affinity‐purified antibodies to recombinant human erythropoietin) combined with iron preparation
Trial: 17369904
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with Poetam
Trial: 17369904
Drug: Sorbifer (iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbifer (iron preparation)
Trial: 14669170
Drug: Pramlintide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (120 microg twice daily or 150 microg 3 times a day)
Trial: 8830301
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg, p.o.)
Trial: 110129
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids plus arginine and histidine infusion
Trial: 30866485
Drug: Skate skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skate skin collagen peptides (SCP) 2000 mg per day for 12 weeks
Trial: 16822117
Drug: Clinic-plus-Internet cognitive-behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-plus-Internet cognitive-behavior therapy
Trial: 8344093
Drug: Bowel lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 2 g acetaminophen dose
Trial: 8344093
Drug: Bowel lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 4 g acetaminophen dose
Trial: 24245978
Drug: 1,064 nm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,064 nm Q-Switched Nd:YAG laser plus chemical peeling with Jessner's solution (Group B)
Trial: 8669100
Drug: FK506 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 (0.2 mg/kg/day)
Trial: 1839993
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fenoterol and ipratropium bromide (200 micrograms and 40 micrograms respectively)
Trial: 28771918
Drug: Positive Psychology
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Psychology Intervention (PPI) followed by Cognitive Behavioural Therapy (CBT)
Trial: 26103559
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with acid-etched surface combined with local application of melatonin gel at the osteotomy site
Trial: 26103559
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with acid-etched surface
Trial: 25050592
Drug: Oxycodone once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone once daily (OOD)
Trial: 16674606
Drug: Oxcarbazepine 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 1,200 mg/day
Trial: 16674606
Drug: Oxcarbazepine 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 1,800 mg/day
Trial: 16674606
Drug: Oxcarbazepine 600
RxNorm normalized name: oxcarbazepine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 600 mg/day
Trial: 15203576
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (IL) administered after meals
Trial: 12468570
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg/d
Trial: 27643171
Drug: Indapamide 1.5
RxNorm normalized name: indapamide 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.5 mg/d
Trial: 15757965
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg every 6 weeks up to week 156
Trial: 12120881
Drug: Thiamphenicol glycinate
RxNorm normalized name: thiamphenicol glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol glycinate hydrochloride (TGH) 1500 mg daily for 10 days
Trial: 12120881
Drug: Clarithromycin 1000
RxNorm normalized name: clarithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1000 mg daily for 10 days
Trial: 2125938
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (NIC) 500 mg with placebo
Trial: 2125938
Drug: Acipimox (AC)
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (AC) 500 mg
Trial: 2125938
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 1500 mg
Trial: 7013865
Drug: L‐Asparaginase consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐Asparaginase consolidation
Trial: 24321801
Drug: Beclometasone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone 100 μg plus formoterol 6 μg as maintenance and reliever treatment
Trial: 8682483
Drug: r‐IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐IFN alpha‐2a (5 million units, subcutaneously, thrice weekly)
Trial: 8682483
Drug: r‐IFN alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐IFN alpha‐2b (5 million units, subcutaneously, thrice weekly)
Trial: 6122694
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate (125 to 500 mg)
Trial: 6122694
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate (500 mg)
Trial: 31213771
Drug: 7% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% lidocaine aerosol (5 sprays, 22.5mg) sprayed into the tracheostomy incision (Group III)
Trial: 30254189
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily
Trial: 28235523
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anesthesia (TIVA) with propofol-remifentanil
Trial: 15901026
Drug: Inhaled anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anesthetic group (propofol-fentanyl-isoflurane)
Trial: 11953965
Drug: Pyramid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyramid treatment strategy (initial NSAIDs, followed by chloroquine or sulfasalazine)
Trial: 2172175
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg body weight FDP
Trial: 419426
Drug: Povidone-iodine solution
RxNorm normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine solution irrigation
Trial: 1731672
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution irrigation
Trial: 10023283
Drug: Propofol 30
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 30 mg
Trial: 19636533
Drug: Intermediate glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate glucose control (target BG 7.8-10.0 mmol/L)
Trial: 17470885
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 mg iv
Trial: 17470885
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg iv
Trial: 2889459
Drug: Bevantolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol (200 mg)
Trial: 18996881
Drug: B-GOS (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-GOS (5.5 g/d)
Trial: 12654764
Drug: ABT-773 (cethromycin)
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-773 (cethromycin) at a dose of 150 mg once a day for 10 days
Trial: 12654764
Drug: ABT-773 (cethromycin)
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-773 (cethromycin) at a dose of 150 mg twice a day for 10 days
Trial: 10218061
Drug: Sorbitol-sweetened sour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol-sweetened sour lemon lozenge
Trial: 10218061
Drug: Sorbitol/xylitol-sweetened artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol/xylitol-sweetened artificial saliva substitute spray
Trial: 8160944
Drug: Indomethacin suppositories
RxNorm normalized name: Indomethacin Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppositories 200 mg p.r. at the end of anaesthesia, followed by 100 mg bd for three days
Trial: 17200359
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab
Trial: 19255824
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 50 mg of losartan plus 12.5 mg of hydrochlorothiazide
Trial: 19255824
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 160 mg of valsartan
Trial: 16421661
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral intake supplementation with a formula enriched with arginine, omega-3 fatty acids and ribonucleic acid for five days (supplemented group; n = 19)
Trial: 15614033
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination of perindopril (2 mg) and indapamide (0.625 mg)
Trial: 15614033
Drug: Stepped-care (valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care (valsartan 40 mg, valsartan 80 mg, hydrochlorothiazide 12.5 mg)
Trial: 9404442
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy (0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months)
Trial: 29676870
Drug: Thiazide-like diuretics
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide-like diuretics (e.g., chlorthalidone, indapamide)
Trial: 20950882
Drug: External Beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Beam Radiation Therapy (EBRT)
Trial: 24502859
Drug: Aripiprazole (2-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (2-15 mg/d)
Trial: 17665078
Drug: 1% propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% propofol + 0.5 mg.ml‐1 ephedrine
Trial: 15343012
Drug: Conventional intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional intensive care treatment (n = 20, controls)
Trial: 11166779
Drug: Etofibrate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofibrate (1 g per day for 1 month)
Trial: 8148216
Drug: Cetirizine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 10 mg orally, 3 h before repeat nasal challenge with histamine
Trial: 24666826
Drug: Half-molar sodium
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-molar sodium lactate infusion (3 ml/kg bolus over 15 minutes followed by 1 ml/kg/h continuous infusion for 24 hours)
Trial: 24666826
Drug: Hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann's solution (3 ml/kg bolus without continuous infusion)
Trial: 17911444
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine (BRC) 2.5 mg/day and prednisone 10 mg/day
Trial: 9525445
Drug: Prednisone 10
RxNorm normalized name: prednisone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 10 mg/day
Trial: 23911057
Drug: Medication Recommendation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Recommendation Tracking Form (MRTF)
Trial: 24496960
Drug: Morphine dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine dosing algorithm (5 μg/kg(1.5)/h for neonates with PNA <10 days)
Trial: 19464028
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol (RAC) 20 mg/hour
Trial: 12105816
Drug: Cornstarch placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornstarch placebo capsule for 90 days
Trial: 7582389
Drug: Xylitol (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (10% solution, infused intravenously over 2 hours)
Trial: 30650446
Drug: Apixaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (10 mg twice daily for 7 days, then 5 mg twice daily thereafter)
Trial: 30650446
Drug: Enoxaparin/warfarin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin/warfarin (1 mg/kg twice daily for ≥ 5 days, followed by warfarin)
Trial: 30650446
Drug: Apixaban (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (with anti-platelet therapy)
Trial: 30650446
Drug: Enoxaparin/warfarin (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin/warfarin (with anti-platelet therapy)
Trial: 18297268
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 25) treated by an implemented insulin algorithm
Trial: 12702522
Drug: Vinorelbine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 20 mg/m(2) on days 1 and 8 (group 1)
Trial: 12702522
Drug: Vinorelbine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 40 mg/m(2) on day 1 (group 3)
Trial: 27451390
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg intravenously every 2 weeks)
Trial: 29477448
Drug: Indacaterol (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol (110 μg) plus glycopyrronium (50 μg) once per day for 14 days
Trial: 17989110
Drug: Pharmacogenetic-guided dosing
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic-guided dosing
Trial: 22534813
Drug: Injection dexamethasone
RxNorm normalized name: dexamethasone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection dexamethasone only (Control)
Trial: 16470128
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 or 80 mg/day
Trial: 15457423
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg for 7 days followed by 21 additional days of fondaparinux
Trial: 11421879
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg b.d. (PAC 250)
Trial: 11421879
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.d. (PAC 500)
Trial: 10423636
Drug: Intravenous prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostaglandin E1 (PGE1) infusion for 24 hours at a mean dosage of 16 +/- 3 ng/kg/min (range, 10-20 ng/kg/min)
Trial: 10423636
Drug: Intravenous prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostaglandin E1 (PGE1) infusion
Trial: 10423636
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Group I)
Trial: 1859751
Drug: Edrophonium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.5 mg kg‐1
Trial: 27438317
Drug: Salsalate (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (3.5 g/d)
Trial: 21899713
Drug: Ursodesoxycholic acid
RxNorm normalized name: Tauroursodesoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodesoxycholic acid (UDCA) 10 mg/kg orally per day for 24 months
Trial: 21899713
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for 24 months
Trial: 9808231
Drug: Conventional dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dairy products (34 g lactose/d)
Trial: 9808231
Drug: Lactose-hydrolyzed dairy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-hydrolyzed dairy products (2 g lactose/d)
Trial: 12730476
Drug: Micronutrient supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplements
Trial: 15215111
Drug: BAL5788 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL5788 at 750 mg
Trial: 15607398
Drug: RSD-2 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSD-2 (2 mg/kg followed by 3 mg/kg)
Trial: 12504938
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 20 mg
Trial: 3016226
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide (0.5 mg/kg/24 h)
Trial: 3016226
Drug: Liquid alginic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid alginic acid‐antacid compound
Trial: 31340982
Drug: Zanubrutinib 160
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 160 mg twice daily
Trial: 12641480
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with an ACE inhibitor-based blood pressure-lowering regimen (perindopril) with or without indapamide
Trial: 1998307
Drug: Diltiazem (60-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60-90 mg qid)
Trial: 18657102
Drug: Framing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Framing of attributes (e.g., cancers found vs. cancers missed)
Trial: 363479
Drug: amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline 25 mg
Trial: 31182062
Drug: Tablet-based intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet-based intervention including a screening questionnaire for violence and a video on violence and safety behaviours.
Trial: 15327617
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 400 microg every 3 hours for a maximum of five doses